Amedisys [AMED] vs DaVita [DVA] Detailed Stock Comparison
Amedisys
NASDAQ
Loading...
DaVita
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Amedisys wins in 6 metrics, DaVita wins in 13 metrics, with 0 ties. DaVita appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Amedisys | DaVita | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 39.28 | 12.76 | DaVita |
| Price-to-Book Ratio | 2.69 | 6.33 | Amedisys |
| Debt-to-Equity Ratio | 35.34 | 825.19 | Amedisys |
| PEG Ratio | 19.75 | 11.49 | DaVita |
| EV/EBITDA | 13.73 | 8.65 | DaVita |
| Profit Margin (TTM) | 3.56% | 6.35% | DaVita |
| Operating Margin (TTM) | 11.70% | 15.70% | DaVita |
| EBITDA Margin (TTM) | 11.70% | 15.70% | DaVita |
| Return on Equity | 6.67% | 57.94% | DaVita |
| Return on Assets (TTM) | 6.52% | 7.15% | DaVita |
| Free Cash Flow (TTM) | $214.29M | $1.47B | DaVita |
| 1-Year Return | 3.26% | -7.70% | Amedisys |
| Price-to-Sales Ratio (TTM) | 1.38 | 0.70 | DaVita |
| Enterprise Value | $3.48B | $23.26B | DaVita |
| EV/Revenue Ratio | 1.45 | 1.77 | Amedisys |
| Gross Profit Margin (TTM) | 43.96% | 33.08% | Amedisys |
| Revenue per Share (TTM) | $73 | $164 | DaVita |
| Earnings per Share (Diluted) | $2.57 | $10.15 | DaVita |
| Beta (Stock Volatility) | 0.90 | 1.09 | Amedisys |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Amedisys vs DaVita Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Amedisys | 0.06% | 2.47% | 3.35% | 6.03% | 9.68% | 11.05% |
| DaVita | 1.42% | -6.48% | -9.94% | -9.84% | -25.37% | -13.56% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Amedisys | 3.26% | -17.51% | -56.17% | 122.43% | 322.87% | 231.39% |
| DaVita | -7.70% | 40.03% | 57.60% | 61.31% | 304.18% | 448.96% |
Performance & Financial Health Analysis: Amedisys vs DaVita
| Metric | AMED | DVA |
|---|---|---|
| Market Information | ||
| Market Cap | $3.32B | $9.26B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 1,047,740 | 1,047,040 |
| 90 Day Avg. Volume | 630,147 | 883,743 |
| Last Close | $100.94 | $129.50 |
| 52 Week Range | $82.15 - $100.99 | $126.07 - $179.60 |
| % from 52W High | -0.05% | -27.90% |
| All-Time High | $325.12 (Jan 25, 2021) | $179.60 (Jan 27, 2025) |
| % from All-Time High | -68.95% | -27.90% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.06% |
| Quarterly Earnings Growth | -0.13% | -0.11% |
| Financial Health | ||
| Profit Margin (TTM) | 0.04% | 0.06% |
| Operating Margin (TTM) | 0.12% | 0.16% |
| Return on Equity (TTM) | 0.07% | 0.58% |
| Debt to Equity (MRQ) | 35.34 | 825.19 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $37.48 | $-4.98 |
| Cash per Share (MRQ) | $10.26 | $10.34 |
| Operating Cash Flow (TTM) | $239.42M | $1.86B |
| Levered Free Cash Flow (TTM) | $300.69M | $1.10B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Amedisys vs DaVita
| Metric | AMED | DVA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 39.28 | 12.76 |
| Forward P/E | 19.75 | 11.49 |
| PEG Ratio | 19.75 | 11.49 |
| Price to Sales (TTM) | 1.38 | 0.70 |
| Price to Book (MRQ) | 2.69 | 6.33 |
| Market Capitalization | ||
| Market Capitalization | $3.32B | $9.26B |
| Enterprise Value | $3.48B | $23.26B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.45 | 1.77 |
| Enterprise to EBITDA | 13.73 | 8.65 |
| Risk & Other Metrics | ||
| Beta | 0.90 | 1.09 |
| Book Value per Share (MRQ) | $37.48 | $-4.98 |
Financial Statements Comparison: Amedisys vs DaVita
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AMED | DVA |
|---|---|---|
| Revenue/Sales | $621.86M | $3.22B |
| Cost of Goods Sold | $348.47M | $2.24B |
| Gross Profit | $273.39M | $983.87M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $72.74M | $433.33M |
| EBITDA | $97.35M | $597.84M |
| Pre-Tax Income | $48.33M | $286.33M |
| Income Tax | $19.27M | $54.12M |
| Net Income (Profit) | $29.05M | $232.22M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AMED | DVA |
|---|---|---|
| Cash & Equivalents | $337.30M | $438.78M |
| Total Current Assets | $662.20M | $3.64B |
| Total Current Liabilities | $488.36M | $2.91B |
| Long-Term Debt | $386.83M | $11.72B |
| Total Shareholders Equity | $1.27B | $1.66B |
| Retained Earnings | $880.25M | $1.70B |
| Property, Plant & Equipment | $229.50M | $11.65B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AMED | DVA |
|---|---|---|
| Operating Cash Flow | $75.50M | $287.94M |
| Capital Expenditures | $-696,000 | $-143.26M |
| Free Cash Flow | $66.29M | $36.75M |
| Debt Repayment | N/A | $-345.97M |
| Common Stock Repurchase | N/A | $-541.85M |
Short Interest & Institutional Ownership Analysis
| Metric | AMED | DVA |
|---|---|---|
| Shares Short | 2.24M | 5.87M |
| Short Ratio | 4.66 | 6.89 |
| Short % of Float | 0.07% | 0.15% |
| Average Daily Volume (10 Day) | 1,047,740 | 1,047,040 |
| Average Daily Volume (90 Day) | 630,147 | 883,743 |
| Shares Outstanding | 32.78M | 80.54M |
| Float Shares | 32.24M | 35.72M |
| % Held by Insiders | 0.02% | 0.50% |
| % Held by Institutions | 0.93% | 0.51% |
Dividend Analysis & Yield Comparison: Amedisys vs DaVita
| Metric | AMED | DVA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |